<DOC>
	<DOCNO>NCT00728442</DOCNO>
	<brief_summary>The objective study evaluate use OncoDoc2 , computerize guideline-based decision support system , could improve compliance multidisciplinary staff meeting decision local clinical practice guideline management non-metastatic breast cancer .</brief_summary>
	<brief_title>Impact OncoDoc2 Guideline Compliance Management Breast Cancer</brief_title>
	<detailed_description>In France , promote quality cancer care , decision currently make accord clinical practice guideline ( CPGs ) regularly organize multidisciplinary staff meeting ( MSMs ) . Dissemination textual CPGs poor impact clinical practice oppose use clinical decision support system ( CDSSs ) know improve compliance CPGs . OncoDoc2 CDSS provide patient-specific recommendation base CPGs non-metastatic female breast cancer management elaborate CancerEst INTERMEDICAL collaboration.The main goal study evaluate effect routine use OncoDoc2 MSMs compliance MSM decision local CPGs . Impact measure compliance rate MSM decision OncoDoc2 recommendation . The design study relies cluster randomize controlled trial . Under assumption baseline compliance rate 70 % without intervention , expect compliance rate 90 % intervention group ( α = 5 % , β = 20 % ) , inter-cluster variability 5 % , 59 decision per center , require number center 3 group , 177 decision arm . The study conduct cancer care center ( public private ) Paris area , France.This prospective trial conduct two step . First , baseline compliance rate measure center . Then , 6 center randomize 2 arm . In intervention arm , OncoDoc2 use MSMs decision time . Every case non-adherence system recommendation justify clinician . In arm MSM , MSM decision record well patient characteristic OncoDoc2 use patient case get system recommendation . In intervention arm , OncoDoc2 recommendation obtain MSM also record , well reason non follow recommendation case MSM decision comply guideline .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Non metastatic , include invasive situ , breast cancer well axillary cancer without breast tumor . At least one therapeutic MSM decision . Breast disease without cancer Metastatic breast cancer Male breast cancer Breast cancer case medical record accessible investigator Management therapeutic breast cancer decision ( diagnostic investigation , treatment followup , delay decisions… )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Clinical practice guideline</keyword>
	<keyword>Guideline adherence</keyword>
	<keyword>Clinical decision support system</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Intervention study</keyword>
</DOC>